
Topic
Androgen Deprivation Therapy (ADT)
Podcasts
Urology # 336Oct 15, 2026Biomarkers in Treatment Intensification for Prostate Cancer

Same risk group, very different benefit. Can biomarkers help identify who needs treatment intensification in prostate cancer? On this episode of BackTable Urology, Dr. Ruchika Talwar and Dr. Angela Jia, a radiation oncologist at University Hospitals Cleveland Medical Center, break down the difference between prognostic and predictive biomarkers and how genomic testing is informing the way clinicians counsel patients. They review trial data suggesting that men with a low genomic score may gain little from adding hormone therapy, along with early prospective evidence that the luminal B subtype may help identify who benefits most from intensification.
Urology # 332Sep 29, 2026The Basics of Advanced Prostate Cancer Management for Urologists

What does a urologist actually need to know to confidently manage advanced prostate cancer in the clinic? On this episode of BackTable Urology, host Dr. Ruchika Talwar interviews Dr. Kristen Scarpato, director of the advanced prostate cancer clinic at Vanderbilt University Medical Center, and Dr. Jason Hafron, chief medical officer of the Michigan Institute of Urology. They break down how the landscape has shifted, why more patients stay in urology for treatment, and how to select and monitor therapy based on disease state, comorbidities, and patient goals.
Urology # 259Sep 9, 2025Prostate Tumor Board: Risk Stratification & Treatment Strategies

Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer.
Tumor Board # 21Aug 19, 2025Prostate Tumor Board: Risk Stratification & Treatment Strategies

Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer.
Urology # 210Jan 21, 2025Personalizing ADT Across the Prostate Cancer Spectrum

What is the role of androgen deprivation therapy (ADT) in prostate cancer treatment? In this episode of the BackTable Urology Podcast, Dr. Rana McKay, a medical oncologist from UC San Diego, joins host Dr. Aditya Bagrodia to discuss the administration of ADT and other management strategies for prostate cancer.
Urology # 206Dec 17, 2024Biochemical Recurrence: Insights from AUA/ASTRO/SUO Guidelines

Have you checked out the AUA/ASTRO/SUO’s recently released guidelines for salvage therapy in prostate cancer biochemical recurrence? In this episode of the BackTable Urology Podcast, guest Dr. Todd Morgan from the University of Michigan and host Dr. Aditya Bagrodia continue with part two of our series on prostate cancer biochemical recurrence management.
Urology # 200Nov 19, 2024Managing Biochemical Recurrence After Prostate Radiation

Biochemical recurrence of prostate cancer can be difficult to diagnose and treat. In this episode of BackTable Urology, where Dr. Aditya Bagrodia hosts Dr. Amar Kishan, a genitourinary radiation oncologist at UCLA, to discuss the complexities of biochemical recurrence and local failure after radiation therapy for prostate cancer.
Urology # 93Apr 19, 2023Management of Advanced Prostate Cancer for the Urologist

On this episode of BackTable Urology, Dr. Aditya Bagrodia and Dr. Rana McKay, a medical oncologist at UC San Diego, discuss guidelines and advances in prostate cancer treatment.
Urology # 53Sep 7, 2022Radiation Therapy for Favorable Intermediate Risk Prostate Cancer

In this episode of BackTable Urology, Dr. Aditya Bagrodia discusses radiation therapy for favorable intermediate-risk prostate cancer with radiation oncologist Dr. Amar Kishan, Chief of the Genitourinary Oncology Service for the Department of Radiation Oncology at UCLA.
Urology # 41Jun 1, 2022Radiotherapy for Unfavorable Intermediate Prostate Cancer

Dr. Neil Desai, a radiation oncologist with UT Southwestern, shares his perspectives on radiation therapy indications, algorithms, side effects, and prognoses for unfavorable intermediate risk prostate cancer patients.